Promising early results for immunotherapy-antiangiogenesis combination

J Natl Cancer Inst. 2014 Nov 23;106(11):dju392. doi: 10.1093/jnci/dju392. Print 2014 Nov.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / immunology*
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies / therapeutic use
  • Antibodies, Monoclonal / immunology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized / immunology
  • Antibodies, Monoclonal, Humanized / therapeutic use
  • B7-H1 Antigen / immunology
  • Bevacizumab
  • Cancer Vaccines / therapeutic use
  • Clinical Trials as Topic
  • Humans
  • Immunosuppressive Agents / pharmacology
  • Immunotherapy* / methods
  • Ipilimumab
  • Neoplasms / drug therapy*
  • Neoplasms / immunology*
  • Vascular Endothelial Growth Factor A / immunology*

Substances

  • Angiogenesis Inhibitors
  • Antibodies
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • B7-H1 Antigen
  • CD274 protein, human
  • Cancer Vaccines
  • Immunosuppressive Agents
  • Ipilimumab
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • pembrolizumab